Dynamic Technology Lab Private Ltd Purchases New Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 17,366 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PBYI. American Century Companies Inc. boosted its stake in Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after buying an additional 366,653 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in Puma Biotechnology during the second quarter valued at approximately $815,000. Frazier Life Sciences Management L.P. boosted its stake in Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after buying an additional 246,264 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Puma Biotechnology during the third quarter valued at approximately $627,000. Finally, Great Point Partners LLC lifted its stake in shares of Puma Biotechnology by 10.6% in the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock valued at $4,846,000 after purchasing an additional 142,916 shares during the last quarter. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Price Performance

NASDAQ:PBYI opened at $3.27 on Wednesday. Puma Biotechnology, Inc. has a 1 year low of $2.22 and a 1 year high of $7.73. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The firm has a market capitalization of $160.52 million, a price-to-earnings ratio of 6.81 and a beta of 1.08. The business has a 50 day simple moving average of $2.86 and a 200-day simple moving average of $3.09.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The company had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. During the same quarter in the previous year, the business earned $0.12 EPS. Equities analysts forecast that Puma Biotechnology, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, November 20th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.